Colorectal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
The observed overexpression of several 5-FU activating genes and DPYD downregulation deduce that chemotherapy naïve colorectal tumors share favorable gene expression profile for 5-FU therapy.
|
27733154 |
2016 |
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
RGD |
Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats.
|
23197286 |
2013 |
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.
|
19020767 |
2008 |
Colorectal Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression.
|
17612628 |
2007 |
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
|
17611699 |
2007 |
Colorectal Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
|
17203168 |
2007 |
Colorectal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
In this study, we analyzed by real-time reverse transcription-PCR (RT-PCR) the expression of DPD and of members of the cellular oscillation machinery, period 1 (Per1), period 2 (Per2), and CLOCK, in primary colorectal tumors and normal colon mucosa derived from the same patients.
|
17699798 |
2007 |
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
The relationship between survival and the expression of dihydropyrimidine dehydrogenase in patients with colorectal cancer.
|
16786143 |
2006 |
Colorectal Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
We present a novel, standardized approach for TP, DPD, and TS mRNA quantification in archival tissue specimens and applied this to a large series of primary colorectal tumors.
|
16132996 |
2006 |
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
In this study, the mRNA expression levels of these 81 selected genes and the genes of 5-FU-related enzymes, including thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and orotate phosphoribosyltransferase (OPRT), were measured using real-time quantitative RT-PCR assays of surgically resected materials from primary colorectal tumors in 22 patients.
|
16477629 |
2006 |
Colorectal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Median gene expression levels of TP and TS did not differ significantly between primary colorectal tumor and corresponding lymph node metastasis but median DPD gene expression levels in the lymph node metastases were significantly higher compared to matched primary colorectal tumors (p=0.015).
|
16391809 |
2006 |
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
|
17047489 |
2006 |
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer.
|
15814641 |
2005 |
Colorectal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
We did not find any significant differences in TS, TP and DPD gene expression between colorectal tumor and surrounding mucosa.
|
15875081 |
2005 |
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
[Thymidylate synthase and dihydropyrimidine dehydrogenase gene expressions in colorectal cancer using the Danenberg tumor profile method].
|
15222106 |
2004 |
Colorectal Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Comparative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in gastric and colorectal cancers.
|
15069545 |
2004 |
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
|
14562021 |
2003 |
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
|
14519634 |
2003 |
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
DPD and TS expressions were measured by reverse transcription-PCR in surgically resected materials of primary colorectal tumors from 37 patients who went on to receive oral treatment of uracil and tegafur and leucovorin for either synchronous or metachronous metastatic diseases.
|
12576451 |
2003 |
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
There was no correlation among DPD, TS, and TP expression values in this set of colorectal tumors, which indicated that these gene expressions are independent variables.
|
10778957 |
2000 |
Colorectal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
The tumor:normal ratio for DPD mRNA, protein, and activity was relatively stable in liver (0.25, 0.55, and 0.51, respectively) but varied considerably in colon (0.085, 0.9, and 1.25, respectively), consistent with enhanced translation of DPD transcript in primary colorectal tumor.
|
10499634 |
1999 |